Health-care companies were mostly flat amid mixed earnings.
Drug giant Pfizer boosted its 2024 revenue projection, alleviating pressure from activist investor Starboard Value.
Swiss drug maker Novartis raised its growth projections for the third time this year after higher third-quarter results topped expectations, boosted by revenue from its blockbuster drugs.
Write to Rob Curran at rob.curran@dowjones.com
(END) Dow Jones Newswires
October 29, 2024 17:45 ET (21:45 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments